Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep;85(6):836–844. doi: 10.1054/bjoc.2001.1991

CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation

G Della Torre 1, B Pasini 2, S Frigerio 1, R Donghi 4, D Rovini 3, D Delia 1, G Peters 5, T J G Huot 5, G Bianchi-Scarra 6, F Lantieri 6, M Rodolfo 1, G Parmiani 1, M A Pierotti 1
PMCID: PMC2375081  PMID: 11556834

Abstract

Physical interaction between CDKN2A/p16 and CDK4 proteins regulates the cell cycle progression through the G1 phase and dysfunction of these proteins by gene mutation is implicated in genetic predisposition to melanoma. We analysed 15 Italian melanoma families for germ line mutations in the coding region of the CDKN2A gene and exon 2 of the CDK4 gene. One novel disease-associated mutation (P48T), 3 known pathological mutations (R24P, G101W and N71S) and 2 common polymorphisms (A148T and Nt500 G>C) were identified in the CDKN2A gene. In a family harbouring the R24P mutation, an intronic variant (IVS1, +37 G>C) of uncertain significance was detected in a non-carrier melanoma case. The overall incidence of CDKN2A mutations was 33.3%, but this percentage was higher in families with 3 or more melanoma cases (50%) than in those with only 2 affected relatives (25%). Noteworthy, functional analysis established that the novel mutated protein, while being impaired in cell growth and inhibition assays, retains some in vitro binding to CDK4/6. No variant in the p16-binding region of CDK4 was identified in our families. Our results, obtained in a heterogeneous group of families, support the view that inactivating mutations of CDKN2A contribute to melanoma susceptibility more than activating mutations of CDK4 and that other genetic factors must be responsible for melanoma clustering in a high proportion of families. In addition, they indicate the need for a combination of functional assays to determine the pathogenetic nature of new CDKN2A mutations. http://www.bjcancer.com © 2001 Cancer Research Campaignhttp://www.bjcancer.com

Keywords: familial melanoma, CDKN2A and CDK4 genes, germ line mutations

Full Text

The Full Text of this article is available as a PDF (120.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker S. J., Markowitz S., Fearon E. R., Willson J. K., Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990 Aug 24;249(4971):912–915. doi: 10.1126/science.2144057. [DOI] [PubMed] [Google Scholar]
  2. Borg A., Sandberg T., Nilsson K., Johannsson O., Klinker M., Måsbäck A., Westerdahl J., Olsson H., Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000 Aug 2;92(15):1260–1266. doi: 10.1093/jnci/92.15.1260. [DOI] [PubMed] [Google Scholar]
  3. Brotherton D. H., Dhanaraj V., Wick S., Brizuela L., Domaille P. J., Volyanik E., Xu X., Parisini E., Smith B. O., Archer S. J. Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d. Nature. 1998 Sep 17;395(6699):244–250. doi: 10.1038/26164. [DOI] [PubMed] [Google Scholar]
  4. Castellano M., Parmiani G. Genes involved in melanoma: an overview of INK4a and other loci. Melanoma Res. 1999 Oct;9(5):421–432. [PubMed] [Google Scholar]
  5. Coleman K. G., Wautlet B. S., Morrissey D., Mulheron J., Sedman S. A., Brinkley P., Price S., Webster K. R. Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J Biol Chem. 1997 Jul 25;272(30):18869–18874. doi: 10.1074/jbc.272.30.18869. [DOI] [PubMed] [Google Scholar]
  6. Delia D., Goi K., Mizutani S., Yamada T., Aiello A., Fontanella E., Lamorte G., Iwata S., Ishioka C., Krajewski S. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Oncogene. 1997 May 8;14(18):2137–2147. doi: 10.1038/sj.onc.1201050. [DOI] [PubMed] [Google Scholar]
  7. Donghi R., Longoni A., Pilotti S., Michieli P., Della Porta G., Pierotti M. A. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest. 1993 Apr;91(4):1753–1760. doi: 10.1172/JCI116385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ghiorzo P., Ciotti P., Mantelli M., Heouaine A., Queirolo P., Rainero M. L., Ferrari C., Santi P. L., De Marchi R., Farris A. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer. 1999 Nov 12;83(4):441–448. doi: 10.1002/(sici)1097-0215(19991112)83:4<441::aid-ijc2>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  9. Goldstein A. M., Fraser M. C., Struewing J. P., Hussussian C. J., Ranade K., Zametkin D. P., Fontaine L. S., Organic S. M., Dracopoli N. C., Clark W. H., Jr Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med. 1995 Oct 12;333(15):970–974. doi: 10.1056/NEJM199510123331504. [DOI] [PubMed] [Google Scholar]
  10. Goldstein A. M., Struewing J. P., Chidambaram A., Fraser M. C., Tucker M. A. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst. 2000 Jun 21;92(12):1006–1010. doi: 10.1093/jnci/92.12.1006. [DOI] [PubMed] [Google Scholar]
  11. Guldberg P., Kirkin A. F., Gronbaek K., thor Straten P., Ahrenkiel V., Zeuthen J. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer. 1997 Sep 4;72(5):780–783. doi: 10.1002/(sici)1097-0215(19970904)72:5<780::aid-ijc13>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  12. Haluska F. G., Hodi F. S. Molecular genetics of familial cutaneous melanoma. J Clin Oncol. 1998 Feb;16(2):670–682. doi: 10.1200/JCO.1998.16.2.670. [DOI] [PubMed] [Google Scholar]
  13. Harland M., Holland E. A., Ghiorzo P., Mantelli M., Bianchi-Scarrà G., Goldstein A. M., Tucker M. A., Ponder B. A., Mann G. J., Bishop D. T. Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer. 2000 May;28(1):45–57. [PubMed] [Google Scholar]
  14. Harland M., Meloni R., Gruis N., Pinney E., Brookes S., Spurr N. K., Frischauf A. M., Bataille V., Peters G., Cuzick J. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet. 1997 Nov;6(12):2061–2067. doi: 10.1093/hmg/6.12.2061. [DOI] [PubMed] [Google Scholar]
  15. Holland E. A., Beaton S. C., Becker T. M., Grulet O. M., Peters B. A., Rizos H., Kefford R. F., Mann G. J. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene. 1995 Dec 7;11(11):2289–2294. [PubMed] [Google Scholar]
  16. Holland E. A., Schmid H., Kefford R. F., Mann G. J. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer. 1999 Aug;25(4):339–348. [PubMed] [Google Scholar]
  17. Koh J., Enders G. H., Dynlacht B. D., Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature. 1995 Jun 8;375(6531):506–510. doi: 10.1038/375506a0. [DOI] [PubMed] [Google Scholar]
  18. Lilischkis R., Sarcevic B., Kennedy C., Warlters A., Sutherland R. L. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer. 1996 Apr 10;66(2):249–254. doi: 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  19. Morgenstern J. P., Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 1990 Jun 25;18(12):3587–3596. doi: 10.1093/nar/18.12.3587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Parry D., Peters G. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol. 1996 Jul;16(7):3844–3852. doi: 10.1128/mcb.16.7.3844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ruas M., Brookes S., McDonald N. Q., Peters G. Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information. Oncogene. 1999 Sep 23;18(39):5423–5434. doi: 10.1038/sj.onc.1202918. [DOI] [PubMed] [Google Scholar]
  22. Ruas M., Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998 Oct 14;1378(2):F115–F177. doi: 10.1016/s0304-419x(98)00017-1. [DOI] [PubMed] [Google Scholar]
  23. Ruiz A., Puig S., Malvehy J., Lázaro C., Lynch M., Gimenez-Arnau A. M., Puig L., Sánchez-Conejo J., Estivill X., Castel T. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J Med Genet. 1999 Jun;36(6):490–493. [PMC free article] [PubMed] [Google Scholar]
  24. Soufir N., Avril M. F., Chompret A., Demenais F., Bombled J., Spatz A., Stoppa-Lyonnet D., Bénard J., Bressac-de Paillerets B. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet. 1998 Feb;7(2):209–216. doi: 10.1093/hmg/7.2.209. [DOI] [PubMed] [Google Scholar]
  25. Tsao H., Benoit E., Sober A. J., Thiele C., Haluska F. G. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res. 1998 Jan 1;58(1):109–113. [PubMed] [Google Scholar]
  26. Wölfel T., Hauer M., Schneider J., Serrano M., Wölfel C., Klehmann-Hieb E., De Plaen E., Hankeln T., Meyer zum Büschenfelde K. H., Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995 Sep 1;269(5228):1281–1284. doi: 10.1126/science.7652577. [DOI] [PubMed] [Google Scholar]
  27. Yarbrough W. G., Aprelikova O., Pei H., Olshan A. F., Liu E. T. Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. J Natl Cancer Inst. 1996 Oct 16;88(20):1489–1491. doi: 10.1093/jnci/88.20.1489. [DOI] [PubMed] [Google Scholar]
  28. Zuo L., Weger J., Yang Q., Goldstein A. M., Tucker M. A., Walker G. J., Hayward N., Dracopoli N. C. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet. 1996 Jan;12(1):97–99. doi: 10.1038/ng0196-97. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES